GROWTH OPPORTUNITIES IN LIQUID BIOPSY, DIAGNOSTICS AND THERAPEUTICS IN MULTIPLE DISORDERS

GROWTH OPPORTUNITIES IN LIQUID BIOPSY, DIAGNOSTICS AND THERAPEUTICS IN MULTIPLE DISORDERS

RELEASE DATE
18-Sep-2020
REGION
Global
Research Code: D759-00-18-00-00
SKU: HC03337-GL-TA_24729

$950.00

Special Price $807.50 save 15 %

In stock
SKU
HC03337-GL-TA_24729

$950.00

$807.50 save 15 %

DownloadLink

Pay by invoice

ENQUIRE NOW

Description

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) contains insights across various diagnostic tests, mostly liquid biopsy, AI, and genomic tests for cancer as well as for rheumatoid arthritis, metabolic diseases, and COVID-19 vaccine. Additionally, it covers therapies for amyotrophic lateral sclerosis and cancer, novel technologies such as teledentistry, novel insulin formulation, biosensing and regenerative medicine for hearing loss, probiotics for gut health of diabetics and CRISPR-based microbiome engineering technology.

The Life Science, Health & Wellness TOE will feature disruptive technology advances in the global life sciences industry. The technologies and innovations profiled will encompass developments across genetic engineering, drug discovery and development, biomarkers, tissue engineering, synthetic biology, microbiome, disease management, as well as health and wellness among several other platforms.

The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.

Keywords: Cancer diagnosis, liquid biopsy, cancer genomics, ctDNA, cell-free DNA, circulating tumor cells, circulating cell-free nucleic acid, circulating cell-free mutant DNA, cancer molecular diagnostic, cancer biomarkers, blood-based detection, lung cancer, NSCLC, non-small cell lung cancer, colorectal cancer, precision oncology, single-cell isolation, COVID-19 diagnosis, COVID-19 vaccine, cardiac disease diagnosis, metabolic disease diagnosis, neurological disorders diagnosis, immune cell characterization, immune-oncology, neurodegenerative diseases, Prosetin, hearing loss, amyotrophic lateral sclerosis, oral health, dental health, oral diseases, teledentistry, skin cancer, insulin formulation, diabetes, Rheumatoid arthritis, microbiome, CRISPR/Cas engineering, biosensing, monoclonal microbials, gut health, probiotic, prebiotic, blood-based tests, synbiotic

Table of Contents

INNOVATIONS IN LIFE SCIENCES, HEALTH & WELLNESS

  • PERSONAL GENOME DIAGNOSTICS INC., US
  • GROWTH OPPORTUNITIES
  • SYSMEX INOSTICS GMBH, GERMANY
  • GROWTH OPPORTUNITIES
  • INIVATA LTD., UK
  • GROWTH OPPORTUNITIES
  • FREENOME, US
  • GROWTH OPPORTUNITIES
  • GUARDANT HEALTH INC., US
  • GROWTH OPPORTUNITIES
  • GRAIL INC., US
  • GROWTH OPPORTUNITIES
  • MENARINI SILICON BIOSYSTEMS S.P.A., ITALY
  • GROWTH OPPORTUNITIES
  • HUMAN LONGEVITY INC., US
  • GROWTH OPPORTUNITIES
  • EPIC SCIENCES, US
  • GROWTH OPPORTUNITIES
  • EVELO BIOSCIENCES
  • GROWTH OPPORTUNITIES
  • PENDULUM DIAGNOSTICS, US
  • GROWTH OPPORTUNITIES
  • WASHINGTON STATE UNIVERSITY, US
  • GROWTH OPPORTUNITIES
  • THRIVE EARLIER DETECTION CORP., US
  • GROWTH OPPORTUNITIES
  • DELFI DIAGNOSTICS, US
  • GROWTH OPPORTUNITIES
  • LEXENT BIO (FOUNDATION MEDICINE), US
  • GROWTH OPPORTUNITIES
  • BASE GENOMICS, UK
  • GROWTH OPPORTUNITIES
  • PROJECT ALS, US
  • GROWTH OPPORTUNITIES
  • MOUTHWATCH, US
  • GROWTH OPPORTUNITIES
  • SKIN ANALYTICS, UK
  • GROWTH OPPORTUNITIES
  • STANFORD UNIVERSITY, US
  • GROWTH OPPORTUNITIES
  • HARVARD MEDICAL SCHOOL, USA
  • GROWTH OPPORTUNITIES
  • ELIGOBIOSCIENCE, FRANCE
  • GROWTH OPPORTUNITIES
  • ROSA BIOTECH, UK
  • GROWTH OPPORTUNITIES
  • UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE, US
  • GROWTH OPPORTUNITIES
  • UNIVERSITY OF OXFORD, UK
  • GROWTH OPPORTUNITIES
  • EPFL INSTITUTE OF BIOENGINEERING, SWITZERLAND
  • GROWTH OPPORTUNITIES

KEY CONTACTS

  • KEY CONTACTS
  • KEY CONTACTS
  • KEY CONTACTS
  • KEY CONTACTS
  • KEY CONTACTS
  • KEY CONTACTS
  • KEY CONTACTS
  • Legal Disclaimer
Related Research
This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) contains insights across various diagnostic tests, mostly liquid biopsy, AI, and genomic tests for cancer as well as for rheumatoid arthritis, metabolic diseases, and COVID-19 vaccine. Additionally, it covers therapies for amyotrophic lateral sclerosis and cancer, novel technologies such as teledentistry, novel insulin formulation, biosensing and regenerative medicine for hearing loss, probiotics for gut health of diabetics and CRISPR-based microbiome engineering technology. The Life Science, Health & Wellness TOE will feature disruptive technology advances in the global life sciences industry. The technologies and innovations profiled will encompass developments across genetic engineering, drug discovery and development, biomarkers, tissue engineering, synthetic biology, microbiome, disease management, as well as health and wellness among several other platforms. The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: Cancer diagnosis, liquid biopsy, cancer genomics, ctDNA, cell-free DNA, circulating tumor cells, circulating cell-free nucleic acid, circulating cell-free mutant DNA, cancer molecular diagnostic, cancer biomarkers, blood-based detection, lung cancer, NSCLC, non-small cell lung cancer, colorectal cancer, precision oncology, single-cell isolation, COVID-19 diagnosis, COVID-19 vaccine, cardiac disease diagnosis, metabolic disease diagnosis, neurological disorders diagnosis, immune cell characterization, immune-oncology, neurodegenerative diseases, Prosetin, hearing loss, amyotrophic lateral sclerosis, oral health, dental health, oral diseases, teledentistry, skin cancer, insulin formulation, diabetes, Rheumatoid arthritis, microbiome, CRISPR/Cas engineering, biosensing, monoclonal microbials, gut health, probiotic, prebiotic, blood-based tests, synbiotic
More Information
No Index No
Podcast No
Industries Healthcare
WIP Number D759-00-18-00-00
Is Prebook No
Ti Codes D759